RECRUITINGOBSERVATIONAL
Use of Biologics for Severe Asthma in Hong Kong
About This Trial
The landscape of biologics therapy used in Hong Kong is currently unknown. The purpose of this study is to conduct a retrospective analysis of the use of biologics treatment for severe asthma in Hong Kong. The study aims to assess the landscape of biologics usage, evaluate the characteristics and conditions of patients before and after receiving biologic therapy, and provide insights into the effectiveness and safety of these treatments in the local population.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients aged 18 years or older.
- Patients diagnosed with severe asthma per the Global Initiative for Asthma (GINA) guidelines.
- Patients who have received biologic therapy for treatment of asthma (including those who received just one dose to allow assessment of the reason for withdrawal)
Who Should NOT Join This Trial:
\- Patients with respiratory diseases with other known significant respiratory diseases, including tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients aged 18 years or older.
* Patients diagnosed with severe asthma per the Global Initiative for Asthma (GINA) guidelines.
* Patients who have received biologic therapy for treatment of asthma (including those who received just one dose to allow assessment of the reason for withdrawal)
Exclusion Criteria:
\- Patients with respiratory diseases with other known significant respiratory diseases, including tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer
Treatments Being Tested
OTHER
no interventions
No interventions, this is an observational study
Locations (1)
Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, HK
Hong Kong, Hong Kong